Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients.
BACKGROUND
Hyperglycemia and insulin resistance frequently occur in critically ill and in morbidly obese (MO) patients. Both conditions are associated with altered serum levels of cytokines and adipokines. In addition, obesity related alterations in adipokine expression contribute to insulin resistance in metabolic syndrome. In this study we examined the serum adipocytokine profile in critically ill patients, MO patients, and healthy blood donors.


METHODS
33 patients who fulfilled the clinical criteria for severe sepsis or septic shock (SP) were prospectively enrolled in this study. A multiplex analysis was performed to evaluate plasma levels of adiponectin, resistin, leptin, active PAI-1, MCP-1, IL-1 alpha, IL-6, IL-8, IL-10, and TNF-alpha in 33 critically ill patients, 37 MO patients and 60 healthy blood donors (BD).


RESULTS
In SP, adiponectin was significantly lowered and resistin, active PAI-1, MCP-1, IL-1 alpha, IL-6, IL-8, IL-10, and TNF-alpha were significantly elevated compared to BD. Leptin levels were unchanged. In MO, adiponectin and IL-8 were significantly lowered, leptin, active PAI-1, MCP-1, IL-1 alpha, IL-6, and IL-10 significantly elevated, whereas resistin was unaltered. In SP, adiponectin correlated negatively with BMI, SAPS II and SOFA scores, while resistin correlated positively with SAPS II and SOFA scores and leptin correlated positively with the BMI. Adiponectin was approximately equally diminished in SP and MO compared to BD. With the exception of active PAI-1, cytokine levels in SP were clearly higher compared to MO.


CONCLUSIONS
A comparable adipocytokine profile was determined in critically ill and MO patients. As in MO, SP showed reduced adiponectin levels and elevated MCP-1, active PAI-1, IL-1 alpha, IL-6, and IL-10 levels. Leptin is only elevated in MO, while resistin, IL-8, and TNF-alpha is only elevated in SP. As in MO patients, increased levels of proinflammatory cytokines and altered levels of adipokines may contribute to the development of insulin resistance in critically ill patients.
Hillenbrand
Andreas
A
Department of General-, Visceral-, and Transplantation Surgery, University Hospital of Ulm, Steinhoevelstr, Ulm, Germany. Andreas.Hillenbrand@uniklinik-ulm.de
Knippschild
Uwe
U
Weiss
Manfred
M
Schrezenmeier
Hubert
H
Henne-Bruns
Doris
D
Huber-Lang
Markus
M
Wolf
Anna M
AM
D054392:Adipokines / Q000097:blood*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000097:blood*; D018805:Sepsis / Q000097:blood*
D054392:Adipokines; D016207:Cytokines
Chest. 2000 Aug;118(2):503-8
10936147
Diabetes. 2002 Oct;51(10):2968-74
12351435
Blood. 2000 Sep 1;96(5):1723-32
10961870
Science. 1995 Jul 28;269(5223):543-6
7624777
Physiol Res. 2001;50(6):589-94
11829320
Biochem Biophys Res Commun. 2005 Sep 9;334(4):1092-101
16039994
Crit Care. 2009;13(4):R112
19589139
J Clin Invest. 1995 May;95(5):2409-15
7738205
Biochem Biophys Res Commun. 2003 Jan 10;300(2):472-6
12504108
Semin Cell Dev Biol. 1999 Feb;10(1):19-29
10355025
Chest. 2000 Apr;117(4):1162-72
10767254
J Clin Endocrinol Metab. 2001 May;86(5):1930-5
11344187
Clin Cancer Res. 2008 Nov 1;14(21):6735-41
18980965
Crit Care. 2009;13(3):R95
19545363
Curr Pharm Des. 2008;14(19):1887-99
18691100
Scand J Infect Dis. 2003;35(9):535-44
14620132
J Biol Chem. 2003 Nov 14;278(46):45777-84
12952969
Physiol Res. 2004;53(2):123-9
15046547
Pathophysiology. 2008 Aug;15(2):123-34
18586471
J Clin Endocrinol Metab. 2006 Nov;91(11):4620-7
16895955
J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S192-203
17989837
Crit Care. 2009;13(4):R105
19570238
PLoS One. 2006 Dec 20;1:e31
17183659
Lancet. 1974 Jul 13;2(7872):81-4
4136544
FASEB J. 2008 Jun;22(6):2012-22
18218920
Diabetes. 1994 Nov;43(11):1271-8
7926300
Lancet. 2003 Jan 18;361(9353):226-8
12547549
N Engl J Med. 2006 Feb 2;354(5):449-61
16452557
Crit Care Clin. 2002 Jul;18(3):509-28
12140911
N Engl J Med. 1999 Jan 14;340(2):115-26
9887164
FEBS Lett. 2002 Oct 23;530(1-3):158-62
12387885
Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51
11287357
J Clin Endocrinol Metab. 1997 Dec;82(12):4196-200
9398739
Chest. 1992 Jun;101(6):1644-55
1303622
Trends Endocrinol Metab. 2002 Jan-Feb;13(1):18-23
11750858
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
19441883
J Neuroendocrinol. 2008 Jan;20(1):120-7
18081560
Curr Opin Pharmacol. 2009 Aug;9(4):447-53
19481975
J Clin Endocrinol Metab. 1999 Jul;84(7):2438-42
10404818
JAMA. 1993 Dec 22-29;270(24):2957-63
8254858
Obesity (Silver Spring). 2006 Dec;14(12):2177-83
17189544
J Clin Endocrinol Metab. 1998 Jan;83(1):280-3
9435456
Circ J. 2010 Feb;74(2):213-20
20065609
Diabetes. 2007 Apr;56(4):1010-3
17287468
Biochem Biophys Res Commun. 2004 Apr 9;316(3):924-9
15033490
Endocrinology. 2004 May;145(5):2273-82
14726444
Crit Care Med. 2007 Jun;35(6):1536-42
17452927